Literature DB >> 32611622

Comparison of PED and FRED flow diverters for posterior circulation aneurysms: a propensity score matched cohort study.

Christoph J Griessenauer1,2, Alejandro Enriquez-Marulanda3, Sissi Xiang4, Tao Hong4, Hongqi Zhang4, Philipp Taussky5, Ramesh Grandhi5, Muhammad Waqas6, Vincent M Tutino6, Adnan H Siddiqui6, Elad I Levy6, Christopher S Ogilvy7, Ajith J Thomas7, Christian Ulfert8, Markus A Möhlenbruch8, Leonardo Renieri9, Nicola Limbucci9, Carmen Parra-Fariñas10, Jan-Karl Burkhardt11, Peter Kan11, Lorenzo Rinaldo12, Giuseppe Lanzino12, Waleed Brinjikji12, Julian Spears13, Erasmia Müller-Thies-Broussalis2,14, Monika Killer-Oberpfalzer2,14, Civan Islak15, Naci Kocer15, Michael Sonnberger16, Tobias Engelhorn17, Mandeep Ghuman18, Victor Xd Yang18, Arsalaan Salehani19, Mark R Harrigan19, Ivan Radovanovic20, Vitor M Pereira20, Timo Krings20, Charles C Matouk21, Karen Chen22, Mohammad Ali Aziz-Sultan22, Mohammad Ghorbani23, Clemens M Schirmer24,2, Oded Goren24, Shamsher S Dalal25, Matthew J Koch26, Christopher J Stapleton26, Aman B Patel26, Thomas Finkenzeller27, Markus Holtmannspötter28, Jan Hendrik Buhk29, Paul Michael Foreman30, Marshall Cress30, Robert Hirschl30, Wolfgang Reith31, Andreas Simgen31, Hendrik Janssen32, Thomas R Marotta13, Adam A Dmytriw13,18,20.   

Abstract

BACKGROUND: Flow diversion is a common endovascular treatment for cerebral aneurysms, but studies comparing different types of flow diverters are scarce.
OBJECTIVE: To perform a propensity score matched cohort study comparing the Pipeline Embolization Device (PED) and Flow Redirection Intraluminal Device (FRED) for posterior circulation aneurysms.
METHODS: Consecutive aneurysms of the posterior circulation treated at 25 neurovascular centers with either PED or FRED were collected. Propensity score matching was used to control for age, duration of follow-up imaging, adjunctive coiling, and aneurysm location, size, and morphology; previously ruptured aneurysms were excluded. The two devices were compared for the following outcomes: procedural complications, aneurysm occlusion, and functional outcome.
RESULTS: A total of 375 aneurysms of the posterior circulation were treated in 369 patients. The PED was used in 285 (77.2%) and FRED in 84 (22.8%) procedures. Aneurysms treated with the PED were more commonly fusiform and larger than those treated with FRED. To account for these important differences, propensity score matching was performed resulting in 33 PED and FRED unruptured aneurysm pairs. No differences were found in occlusion status and neurologic thromboembolic or hemorrhagic complications between the two devices. The proportion of patients with favorable functional outcome was higher with FRED (100% vs 87.9%, p=0.04).
CONCLUSION: Comparative analysis of PED and FRED for the treatment of unruptured posterior circulation aneurysms did not identify significant differences in aneurysm occlusion or neurologic complications. Variations in functional outcomes warrant additional investigations. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  aneurysm; embolic; flow diverter; intervention; posterior fossa

Mesh:

Year:  2020        PMID: 32611622     DOI: 10.1136/neurintsurg-2020-016055

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  2 in total

1.  Retrospective analysis of intracranial aneurysms after flow diverter treatment including color-coded imaging (syngo iFlow) as a predictor of aneurysm occlusion.

Authors:  Andreas Simgen; Christine Mayer; Michael Kettner; Ruben Mühl-Benninghaus; Wolfgang Reith; Umut Yilmaz
Journal:  Interv Neuroradiol       Date:  2021-06-09       Impact factor: 1.764

2.  Use of flow diverter device in basilar artery for aneurysm treatment: Case series and literature review.

Authors:  Chuanchuan Wang; Deyuan Zhu; Xiaolong Xu; Yu Zhou; Rui Zhao; Qiang Li; Pengfei Yang; Qinghai Huang; Yi Xu; Jianmin Liu; Yibin Fang
Journal:  Front Neurol       Date:  2022-08-17       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.